Testing a medicine to reduce inflammation in pneumonia patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests if a medicine called icosapent ethyl can reduce inflammation in blood vessels for adults hospitalized with pneumonia. It aims to see if this treatment can help prevent complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are hospitalized with pneumonia confirmed by chest imaging and symptoms like fever, cough, or mucus.
- You are 18 years or older.
- You do not have an active inflammatory condition such as rheumatoid arthritis, Crohn's disease, or lupus.
- You have not had cancer (except certain skin cancers or early cervical cancer) in the past 3 years.
- You are not pregnant, breastfeeding, or planning to become pregnant without using two forms of birth control.
- You are not allergic to icosapent ethyl, fish, or shellfish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a prescription fish-oil medicine called icosapent ethyl can improve heart health by reducing plaques (fatty deposits) in the arteries, lowering inflammation, and helping the heart remodel (recover) after a heart event. It is designed for people with heart disease and high triglycerides.
This trial tests a new medication called OPT101 for people hospitalized with pneumonia and sepsis (a severe infection that affects the whole body). The drug may help reduce inflammation and improve oxygen levels. The study focuses on those who need extra oxygen but are not yet on a breathing machine.
This trial tests whether adding an experimental herbal medicine (NRICM102) to standard antibiotics can help adults hospitalized with community-acquired pneumonia recover faster. It is a phase 2 study, meaning the treatment is still being tested for safety and effectiveness.
This study tests whether a purified omega-3 fatty acid called icosapent ethyl can reduce inflammation and shrink high-risk plaques in your heart arteries. It uses a special PET/CT scan to see if the medicine helps stabilize these plaques over time.
This trial tests a new drug called SR1375 for adults with severe community-acquired pneumonia (a lung infection) who are not improving with standard antibiotics. It may help reduce inflammation and speed up recovery.
This Phase 3 trial tests whether an anti-clot “blood thinner” can reduce complications from community-acquired pneumonia in hospitalized adults who need extra oxygen. It may help by lowering harmful clot-related effects during serious lung infection.
Hear when a new Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.